Congenital amegakaryocytic thrombocytopenia (CAMT) is a rare inherited BM failure syndrome characterized by severe thrombocytopenia with reduced or absent megakaryocytes in the BM, absence of physical anomalies and progression into aplastic anemia and secondary myeloid malignancies. It is caused by a mutation in the c-mpl gene, resulting in a complete loss or altered function of the TPO receptor.
If untreated, CAMT is a fatal disease with mortality of patients early in life secondary to hemorrhages and/or development of myelodysplasia and AML. The only present curative treatment of this disease is hematopoietic SCT (HSCT). The treatment of choice is transplantation from a matched-related donor. Transplantation from unrelated donors has been reported but carries an increased risk of rejection, GVHD and transplant-related morbidity. 1, 2 We report three patients with CAMT (Table 1) ; all received a T-cell-depleted transplant from an unrelated donor. All three patients engrafted successfully, had minimal transplant-related toxicities and no evidence of GVHD.
Our three patients were diagnosed with CAMT at birth after presenting with signs related to skin and mucosal bleeding. Genetic testing confirmed a mutation in both alleles of the c-mpl gene in two patients, confirming the diagnosis of CAMT.
In October 1997, at age 3, patient 1 underwent a conditioning regimen with hyperfractionated TBI, thiotepa, CY and anti-thymocyte globulin (ATG), followed by a soybean agglutinin negative, E-rosette negative (SBA-E-) T-cell-depleted BM transplant from a 10/10 HLA-antigenmatched unrelated donor without any post-transplant immunosuppression.
In May 2006, at age 4, patient 2 underwent cytoreduction with melphalan, thiotepa, fludarabine and ATG, followed by a T-cell-depleted (CD34 þ E-) peripheral blood SCT from a 9/10-matched unrelated donor without any posttransplant immunosuppression.
In March 2008, at age 2, patient 3 underwent cytoreduction with BU, melphalan, fludarabine and ATG and received a SBA-E-T-cell-depleted BM transplant from a 10/10-matched unrelated donor. Because of a higher than expected CD3 þ cell dose in the graft, she received tacrolimus for GVHD prophylaxis.
Patients are currently 13, 4 and 3 years post-transplant, respectively, in remission with no GVHD, normal blood counts and full donor chimerism. Patient 1 suffers from radiation-induced bilateral posterior subcapsular cataracts and growth retardation secondary to growth hormone deficiency, and patient 3 suffers from mild gross motor delays and failure to thrive probably associated with her underlying disease. 1 Transplantation from a matched-related donor is considered the standard of care. However, transplantation from unrelated donors has been associated with increased risk of delayed engraftment, graft rejection, organ toxicity and GVHD. 2 A total of 11 patients with CAMT who received transplants from unrelated donors have been described in the literature (Table 2) . [1] [2] [3] [4] [5] [6] [7] [8] Nine patients received unmodified grafts from matched-unrelated donors, and two patients received one allele mismatched-unrelated cord-blood transplants. Three of the 11 patients failed to engraft: One patient following an unmodified BMT from a matched-unrelated donor after cytoreduction with TBI/ CY, one patient following an unmodified BMT from a matched-unrelated donor after cytoreduction with BU/CY/ATG and one patient following a single HLA allele mismatched-unrelated cord-blood transplant after cytoreduction with TBI/CY/methylprednisolone/ATG. All patients received post-transplant immunosuppression for GVHD prophylaxis. Seven of the eight engrafted patients developed grade 1-2, and one patient developed grade 4 acute GVHD. One patient developed extensive chronic GVHD of the skin, and two patients developed limited chronic GVHD. The incidence of chronic GVHD following unrelated donor transplants administered to children with leukemia or aplastic anemia population ranges from 59 to 65%. 9 Thus, chronic GVHD continues to be an important factor affecting the overall outcome following allogeneic transplantation and is associated with an increased risk of morbidity and mortality. The most successful approach for the prevention of GVHD is by the removal of T cells from the allograft. In our three cases, the decision was to proceed to transplant, using T-cell-depleted grafts in order to prevent GVHD. All three patients were engrafted and none had developed evidence of GVHD.
In early reports, T-cell-depleted SCTs were associated with an increased risk of graft rejection. We have proceeded to overcome this complication by enhancing T-cell-specific immunosuppression in the transplant cytoreductive regimens and/or by increasing the cell doses of the grafts. 10 Our first patient received a T-cell-depleted graft from a 10/10 matched-unrelated donor after preparation with TBI/thiotepa/CY/ATG. The TBI-containing conditioning regimen was chosen based on our prior experience with T-cell-depleted transplants for children with leukemia.
Since the transplant of this first patient, we have been able to develop chemotherapy-based cytoreductive regimens, which have insured consistent engraftment of T-cell-depleted grafts, without the need for TBI. Our two subsequent patients were treated according to such protocols open at MSKCC at the time of transplant. Thus, patients 2 and 3 received T-cell-depleted grafts from a 9/10-0 and 10/10-matched unrelated donors after preparation with melphalan/thiotepa/fludarabine/ATG and melphalan/BU/fludarabine/ATG, respectively. Both patients were engrafted with full donor chimerism. Although all three patients were heavily pre-transfused and two of them had confirmed aplastic anemia before HSCT, all engrafted, had limited transplant-related toxicities, sustained long-term engraftment with full donor chimerism and did not develop GVHD.
In summary, T-cell-depleted HSCT can be performed in patients with CAMT or other BM failure syndromes regardless of their transfusion status, thereby limiting the risks of GVHD without increased risks of rejection. Such results should encourage proceeding to transplantation from unrelated donors for patients with CAMT earlier in the course of their disease, in order to avoid the risks of bleeding, transfusion allo-sensitization and development of aplastic anemia and secondary malignancies. Chemotherapy-based cytoreductive regiments and T-cell-depleted SCTs from unrelated donors should also be considered for other inherited BM failure syndromes. 
